Status:
UNKNOWN
Effect of JKB-122 on Prednisolone and Azathioprine Induced Remission in Autoimmune Hepatitis (AIH)
Lead Sponsor:
TaiwanJ Pharmaceuticals Co., Ltd
Conditions:
Autoimmune Hepatitis
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This is a Phase 2 study. All patients will receive prednisolone and AZA as standard of care (SOC) during the study. At the end of the study, all data collected will be analyzed the efficacy and safety...
Detailed Description
JKB-122 has been demonstrated effective reducing aminotransferase in refractory AIH patients with SOC.This is a new Phase 2 study to find an optimal dose for relevant phase 3 study in newly diagnostic...
Eligibility Criteria
Inclusion
- Male or female, 18 to 65 years old.
- If female of childbearing potential, must not be pregnant or breastfeeding and either postmenopausal (no menses for previous 12 months) or using an effective method of birth control.
- Probable or definite diagnosis of autoimmune hepatitis according to the International Autoimmune Hepatitis Study Group criteria.
- New diagnosis of AIH that requires treatment according to the current EASL guidelines.
- Has elevated liver test results (ALT) at least 5x ULN at screening.
- Is capable of understanding and signing the informed consent document.
Exclusion
- Overlap syndrome with Primary Sclerosing Cholangitis (PSC) or Primary Biliary Cholangitis (PBC)
- Has cirrhosis on liver biopsy, or Child-Pugh score greater than 6 at screening.
- Has human immunodeficiency virus (HIV) or is hepatitis B virus or HCV positive.
- Has history of alcohol intake \> 25 g/day within the past six months.
- Severe anemia, leukopenia , or thrombocytopenia.
- Known intolerances to prednisolone or azathioprine.
- Current treatment with prednisone/prednisolone and/or immunosuppressive medication for an indication other than autoimmune hepatitis
- Has a known or suspected central nervous system disorder that may predispose to seizures or lower the seizure threshold
- Has unstable and uncontrollable hypertension (\>180/110 mmHg)
- Has current malignancy or a history of malignancy (within the past 5 years), except basal or non-metastatic squamous cell carcinoma of the skin that has been treated successfully.
- Has any form of current substance abuse, psychiatric disorder or a condition that, in the opinion of the Investigator, may invalidate communication with the Investigator.
Key Trial Info
Start Date :
November 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04371718
Start Date
November 1 2020
End Date
February 1 2024
Last Update
September 1 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.